Sign In
Buy ZYME
$22.86
-0.260 (-1.12%)
At Close: Jul 24, 2026
Zymeworks Provides Corporate Update and Reports First Quarter 2026 Financial Results
04:05pm, Thursday, 07'th May 2026
Jazz announced U.S. FDA acceptance with Priority Review of Supplemental Biologics License Application (sBLA) for zanidatamab in first-line HER2-positive unresectable locally advanced or metastatic gas
Zymeworks (NASDAQ:ZYME) and ADVANZ PHARMA (OTCMKTS:CXRXF) Financial Contrast
02:06am, Monday, 27'th Apr 2026
Zymeworks (NASDAQ: ZYME - Get Free Report) and ADVANZ PHARMA (OTCMKTS:CXRXF - Get Free Report) are both manufacturing companies, but which is the better business? We will contrast the two companies ba
Zymeworks Highlights Royalty-Fueled Pivot at Bloom Burton, Eyes Multibillion-Dollar Ziihera
03:12am, Sunday, 26'th Apr 2026
Zymeworks (NASDAQ: ZYME) used a presentation at the Bloom Burton conference to outline how the company is repositioning itself around its first approved product and a growing stream of royalty and mil
Zymeworks Inc. (NASDAQ:ZYME) Receives Consensus Rating of “Moderate Buy” from Analysts
04:24am, Thursday, 23'rd Apr 2026
Shares of Zymeworks Inc. (NASDAQ: ZYME - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the thirteen ratings firms that are covering the firm, Marketbeat Ratings
Zymeworks Presents New Phase 1 Data for ZW191, a Folate Receptor Alpha-Targeting ADC at AACR Annual Meeting 2026
05:30pm, Tuesday, 21'st Apr 2026
VANCOUVER, British Columbia, April 21, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pip
Six poster presentations showcase Zymeworks' next-generation ADC programs, including multiple first-in-class pan-RAS inhibitor ADCs Data highlight efficacy, tumor-selective delivery, and favorable t
Zymeworks to Report First Quarter 2026 Financial Results and Host Conference Call on May 7, 2026
06:00am, Thursday, 16'th Apr 2026
VANCOUVER, British Columbia, April 16, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pip
Zymeworks Announces Additional Leadership Appointments to Advance Next Phase of Growth
06:00am, Thursday, 09'th Apr 2026
• Adam Schayowitz, Ph.D., MBA appointed as Head of R&D • Scott Platshon appointed as Chief Business Officer
Capricorn Fund Managers Ltd Buys Shares of 1,022,840 Zymeworks Inc. $ZYME
04:43am, Monday, 06'th Apr 2026
Capricorn Fund Managers Ltd purchased a new position in shares of Zymeworks Inc. (NASDAQ: ZYME) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange
Neoleukin Therapeutics (NASDAQ:NLTX) & Zymeworks (NASDAQ:ZYME) Critical Contrast
01:24am, Monday, 06'th Apr 2026
Neoleukin Therapeutics (NASDAQ: NLTX - Get Free Report) and Zymeworks (NASDAQ: ZYME - Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two
Zymeworks Appoints Kristin Stafford as Chief Financial Officer
06:00am, Wednesday, 01'st Apr 2026
VANCOUVER, British Columbia, April 01, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pi
Zymeworks Receives U.S. FDA Fast Track Designation for ZW191, an FRα-Targeting Antibody-Drug Conjugate
06:00am, Monday, 30'th Mar 2026
VANCOUVER, British Columbia, March 30, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pi
Zymeworks Announces Participation in Upcoming Investor Conferences
06:00am, Tuesday, 24'th Mar 2026
VANCOUVER, British Columbia, March 24, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pi
Zymeworks Announces Presentations for Ziihera® (zanidatamab-hrii) at 2026 AACR Annual Meeting
07:46am, Wednesday, 18'th Mar 2026
VANCOUVER, British Columbia, March 18, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pip
Zymeworks to Present Clinical and Preclinical Data on ADC Programs Including Novel RAS ADC Platform at AACR Annual Meeting
05:02pm, Tuesday, 17'th Mar 2026
VANCOUVER, British Columbia , March 17, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pi
